Please login to the form below

Not currently logged in
Email:
Password:

Alnylam teams with Isis on joint startup

Alnylam forms jv company with Isis to commercialise microRNA-derived (miRN) drugs in the US

US-based Alnylam Pharmaceuticals has formed a joint venture (jv) company, Regulus Therapeutics, with Isis Pharmaceuticals to commercialise microRNA-derived (miRN) drugs in the US.

Regulus will combine technologies from Alnylam and Isis Pharmaceuticals to create the jv, which will be controlled by a separate management team, board of directors and scientific advisory board. The new firm will be chaired by Nobel prize winner, David Baltimore.

Alnylam added that the company will make an initial investment of USD 10m in Regulus, and will share future funding of the venture with Isis. Both Alnylam and Isis have granted the new company exclusive licenses to miRNA technology of Isis and Alnylam.

MiRN drugs are expected to be able to regulate multiple human genes with potential to treat a number of presently unmet medical needs.

Alnylam develops drugs which implement RNA-interference (RNAi) technology that works by switching off damaged or lethal genes thereby treating diseases. Alnylam reported a FY06 net loss of USD 34.6m on sales of USD 26.9m.

30th September 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Creative Medical Research

Specialising in medical device market research and participant recruitment human factors research, our approach is people-centric. We thrive on making...

Latest intelligence

London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...
The Future of Pharma sales: fast forward to 2029
Change is inevitable, and necessary, for growth in business....
International Women's Day - 8 March 2019
International Women's Day has been celebrated since its inception in 1911. But how far have we come?...

Infographics